XTX Topco Ltd Acquires 6,024 Shares of Lexaria Bioscience Corp. (NASDAQ:LEXX)

XTX Topco Ltd increased its stake in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX) by 47.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 18,626 shares of the company’s stock after acquiring an additional 6,024 shares during the period. XTX Topco Ltd’s holdings in Lexaria Bioscience were worth $57,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Armistice Capital LLC bought a new stake in Lexaria Bioscience during the second quarter worth approximately $2,836,000. Renaissance Technologies LLC acquired a new position in shares of Lexaria Bioscience during the second quarter worth approximately $63,000. Finally, HighTower Advisors LLC bought a new stake in shares of Lexaria Bioscience in the third quarter valued at approximately $40,000. 13.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Lexaria Bioscience in a research note on Monday, December 2nd.

Lexaria Bioscience Trading Up 0.9 %

Shares of LEXX stock opened at $2.23 on Monday. The company has a market capitalization of $38.92 million, a P/E ratio of -4.74 and a beta of 0.99. The stock has a 50 day moving average of $2.36 and a two-hundred day moving average of $2.87. Lexaria Bioscience Corp. has a 12 month low of $1.20 and a 12 month high of $6.85.

Insiders Place Their Bets

In other news, CEO Richard Christopher bought 22,828 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was acquired at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the transaction, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at $51,134.72. This trade represents a ? increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 26.40% of the company’s stock.

Lexaria Bioscience Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.